NT-proAtrial Natriuretic Peptide as a possible biomarker of cardiopulmonary involvement in sarcoidosis

European Journal of Internal Medicine

Volumn 24, Issue 3, 2013, Pages 278-284

  Magrì, Damiano ^a   Agostoni, Piergiuseppe ^b,c   Ricotta, Agnese ^a   Pisani, Lara ^a,d   Cauti, Filippo Maria ^a   Onofri, Alessandro ^a   Bruno, Pierdonato ^a   Ricci, Alberto ^a   Volpe, Massimo ^a,e   Marchitti, Simona ^e   Mariotta, Salvatore ^a   Rubattu, Speranza ^a,e  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e IRCCS NEUROMED   (Italy)

Author keywords

Atrial natriuretic peptide; Lung diffusion capacity; Myocardial dysfunction; Pulmonary sarcoidosis; Tissue Doppler imaging

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; HEMOGLOBIN; NT PRO ATRIAL NATRIURETIC FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTERIAL PRESSURE; ARTICLE; BODY MASS; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART PERFORMANCE; HEMOGLOBIN DETERMINATION; HUMAN; LUNG CIRCULATION; LUNG FUNCTION TEST; LUNG SARCOIDOSIS; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RESTING HEART RATE; SARCOIDOSIS; TISSUE DOPPLER IMAGING;

AGED; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTEIN PRECURSORS; RESPIRATORY FUNCTION TESTS; SARCOIDOSIS; VASCULAR RESISTANCE; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 84875210788     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2012.12.010     Document Type: Article

References (30)

1. R.C. Iannuzzi, Ba Rybicki, and A.S. Teirstein Sarcoidosis N Engl J Med 357 2007 2153 2165
2. A.F. Shorr, D.L. Helman, and D.B. Davies Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics Eur Respir J 25 2005 783 788
3. C. Emirgil, B.J. Sobol, and W.H. Herbert The lesser circulation in pulmonary fibrosis secondary to sarcoidosis and its relationship to respiratory function Chest 60 1971 371 378
4. T. Takemura, Y. Matsui, and S. Saiki Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases Hum Pathol 23 1992 1216 1223
5. T. Handa, S. Nagai, and S. Miki Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis Chest 129 2006 1246 1252
6. D.Y. Sue, A. Oren, and J.E. Hansen Diffusing capacity for carbon monoxide as a predictor of gas exchange during exercise N Engl J Med 316 1987 1301 1306
7. C. Lamberto, H. Nunes, and P. Le Toumelin Membrane and capillary blood components of diffusion capacity of the lung for carbon monoxide in pulmonary sarcoidosis. Relation to exercise gas exchange Chest 125 2004 2061 2068
8. R.P. Baughman, P.J. Engel, and L. Taylor Survival in sarcoidosis- associated pulmonary hypertension: the importance of hemodynamic evaluation Chest 138 2010 1078 1085
9. E. Gialafos, A. Rapti, and V. Kouranos Detection of right ventricular dysfunction by tissue Doppler imaging in asymptomatic patients with pulmonary sarcoidosis Eur Respir J 37 2011 212 215
10. S. Rubattu, S. Sciarretta, and V. Valenti Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases Am J Hypertens 21 2008 733 741
11. H. Yasutake, Y. Seino, and M. Kashiwagi Detection of cardiac sarcoidosis using cardiac markers and myocardial integrated backscatter Int J Cardiol 102 2005 259 268
12. T. Date, T. Shinozaki, and M. Yamakawa Elevated plasma brain natriuretic peptide level in cardiac sarcoidosis patients with preserved ejection fraction Cardiology 107 2007 277 280
13. H.K. Jin, R.H. Yang, and R.M. Thornton Atrial natriuretic peptide lowers pulmonary arterial pressure in hypoxia-adapted rats J Appl Physiol 65 1988 1729 1735
14. L. Zhao, N.A. Mason, and J.W. Strange Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity Circulation 107 2003 234 237
15. V. Louzier, S. Eddahibi, and B. Raffestin Adenovirus-mediated atrial natriuretic protein expression in the lung protects rats from hypoxia-induced pulmonary hypertension Hum Gene Ther 12 2001 503 513
16. Statement of sarcoidosis: joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee Am J Respir Crit Care Med 160 1999 736 755
17. Official statement of the ATS: standardization of spirometry Am J Respir Crit Care Med 152 1995 1107 1136
18. J.E. Cotes, D.J. Chinn, and P.H. Quanjer Standardization of the measurement of transfer factor (diffusing capacity): Report Working Party Standardization of Lung Function Tests, European Community for Coal and Steel; official position of the European Respiratory Society Eur Respir J Suppl 16 1993 41 52
19. F.J.W. Roughton, and R.E. Forster Relative importance of diffusion and chemical reaction rate in determining rate of exchange of gases in the human lung, with special references to true diffusing capacity of pulmonary membrane and volume of blood in the lung capillaries J Appl Physiol 2 1957 290 302 [22]
20. S. Sciomer, D. Magrì, and R. Badagliacca Non-invasive assessment of pulmonary hypertension: Doppler-echocardiography Pulm Pharmacol Ther 20 2007 135 140
21. L.E. Sade, O. Gülmez, and U. Ozyer Tissue Doppler study of the right ventricle with a multisegmental approach: comparison with cardiac magnetic resonance imaging J Am Soc Echocardiogr 22 2009 361 368
22. F. Paneni, M. Gregori, and G.M. Ciavarella Relation between right and left ventricular function in patients undergoing chronic dialysis J Cardiovasc Med (Hagerstown) 2011 10.2459/JCM.0b013e32834eacf0
23. R.M. Lang, M. Bierig, and R.B. Devereux Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendation for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standard Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Society of Echocardiograph, a brunch of the European Society of Cardiology J Am Soc Echocardiogr 18 2005 1440 1463
24. H. Nunes, M. Humbert, and F. Capron Pulmonary hypertension associated with sarcoidosis, haemodynamics and prognosis Thorax 61 2006 68 74
25. C.C. Hsia Recruitment of lung diffusing capacity: update of concept and application Chest 122 2002 1774 1783
26. J.R. Klinger, L. Pietras, and R. Warburton Reduced oxygen tension increases atrial natriuretic peptide release from atrial cardiocytes Exp Biol Med 226 2001 847 853
27. B. Raffestin, M. Levame, and S. Eddahibi Pulmonary vasodilatory action of endogenous atrial natriuretic factor in rats with hypoxic pulmonary hypertension. Effects of monoclonal atrial natriuretic factor antibody Circ Res 70 1992 184 192
28. S. Rubattu, A. Barbato, and S. Marchitti Determinants of N-terminal proatrial natriuretic peptide plasma levels in a survey of adult male population from Southern Italy J Hypertens 28 2010 1638 1645
29. B.S. Edwards, R.S. Zimmerman, and T.R. Schwab Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor Circ Res 62 1988 191 195
30. R. Matthews, T. Bench, H. Meng, D. Franceschi, N. Relan, and D.L. Brown Diagnosis and monitoring of cardiac sarcoidosis with delayed-enhanced MRI and 18F-FDG PET-CT J Nucl Cardiol 19 2012 807 810